相关实验视频

Updated: Jul 18, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

一种通用方法,用于计算复位纠正瘤EQD2值在广泛的临床情况下,包括中断治疗

Roger Dale¹, Georgios Plataniotis², Bleddyn Jones³

¹Department of Surgery and Cancer, Faculty of Medicine, Imperial College, London, UK.

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)

|January 10, 2024

概括

在放射治疗中,准确的瘤等效剂量 (EQD2) 计算需要考虑瘤的重新扩散. 本研究引入了一种使用生物有效剂量 (BED) 的系统方法,以提高EQD2的准确性,特别是在复杂的时间表中.

科学领域:

辐射瘤学辐射瘤学
医学物理医学物理
放射生物学的放射生物学

背景情况:

2 Gy 分数 (EQD2) 的等效剂量是正常组织的标准.
瘤重新填充可能会导致EQD2计算中的重大错误.
现有的方法可能会过度简化瘤对放射治疗计划的反应.

研究的目的:

为计算瘤EQD2值提出一个系统的方法.
为了将瘤重组效应纳入EQD2计算.
提供一种适用于各种放射治疗方案和临床情景的方法.

主要方法:

使用生物有效剂量 (BED) 的概念.
引入一个因子 (f) 来考虑EQD2,交付时间和重新定居之间的相互依赖.
为复杂的案例开发一个公式 (EQD2 = A × BEDref - B).

主要成果:

拟议的方法准确地计算了瘤EQD2,包括重新定居.
有一个过渡性BED值,低于这个值,更简单的方法是有效的.
与过于简单的方法相比,观察到显著的差异.

结论:

开发的方法提供了精确的瘤EQD2估计跨不同的放射治疗计划.
这种方法对临床决策有价值,包括中断治疗.
准确的EQD2计算对于优化放射治疗结果至关重要.

关键词:

相当剂量以 2Gy 分数表示.线性-正方形建模的模型.相当于瘤治疗的药物

更多相关视频

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

相关概念视频

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...